{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:47Z","timestamp":1772120027630,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01403-3","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:56:25Z","timestamp":1768974985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Retrospective Analysis of HAIP Therapy in Metastatic Colorectal Cancer: Efficacy, Safety, and Prognostic Factors"],"prefix":"10.1007","volume":"57","author":[{"given":"Allante","family":"Milsap","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed","family":"Kazmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Kainthla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salwan","family":"Al Mutar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"issue":"1","key":"1403_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"1403_CR2","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.jcmgh.2023.08.012","volume":"16","author":"RK Patel","year":"2023","unstructured":"Patel RK, Rahman S, Schwantes IR, et al. Updated management of colorectal cancer liver metastases: scientific advances driving modern therapeutic innovations. Cell Mol Gastroenterol Hepatol. 2023;16(6):881\u201394. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.08.012.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"7","key":"1403_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/sj.bjc.6603033","volume":"94","author":"PC Simmonds","year":"2006","unstructured":"Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982\u201399. https:\/\/doi.org\/10.1038\/sj.bjc.6603033.","journal-title":"Br J Cancer"},{"issue":"3","key":"1403_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/sla.0b013e3181b4539b","volume":"250","author":"MC De Jong","year":"2009","unstructured":"De Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis. Ann Surg. 2009;250(3):440\u20138. https:\/\/doi.org\/10.1097\/sla.0b013e3181b4539b.","journal-title":"Ann Surg"},{"issue":"4","key":"1403_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3816\/ccc.2008.n.032","volume":"7","author":"DG Power","year":"2008","unstructured":"Power DG, Healey-Bird BR, Kemeny NE. Regional chemotherapy for liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2008;7(4):247\u201359. https:\/\/doi.org\/10.3816\/ccc.2008.n.032.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"1403_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3747\/co.21.1577","volume":"21","author":"PJ Karanicolas","year":"2013","unstructured":"Karanicolas PJ, Metrakos P, Chan K, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol. 2013;21(1):129. https:\/\/doi.org\/10.3747\/co.21.1577.","journal-title":"Curr Oncol"},{"issue":"6","key":"1403_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1200\/jco.1984.2.6.595","volume":"2","author":"N Kemeny","year":"1984","unstructured":"Kemeny N, Daly J, Oderman P, et al. Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol. 1984;2(6):595\u2013600. https:\/\/doi.org\/10.1200\/jco.1984.2.6.595.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1403_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdv548","volume":"27","author":"FA L\u00e9vi","year":"2016","unstructured":"L\u00e9vi FA, Boige V, Hebbar M, Smith D, Lep\u00e8re C, Focan C, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in a multicenter trial (OPTILIV). Ann Oncol. 2016;27(2):267\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdv548.","journal-title":"Ann Oncol"},{"key":"1403_CR9","doi-asserted-by":"publisher","unstructured":"Meyblum L, Faron M, Deschamps F, Kobe A, Bonnet B, Boileve A, et al. Safety and efficacy of percutaneous arterial Port implantation for hepatic arterial infusion chemotherapy. Eur Radiol. 2025;in press. https:\/\/doi.org\/10.1007\/s00330-024-10887-1.","DOI":"10.1007\/s00330-024-10887-1"},{"issue":"6","key":"1403_CR10","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1148\/rg.316115507","volume":"31","author":"KT Brown","year":"2011","unstructured":"Brown KT. Percutaneous transhepatic arterial and portal venous interventions for hepatic malignancy: anatomy and technique. Radiographics. 2011;31(6):1613\u201330. https:\/\/doi.org\/10.1148\/rg.316115507.","journal-title":"Radiographics"},{"issue":"1","key":"1403_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/00000658-199307000-00008","volume":"218","author":"S Iwatsuki","year":"1993","unstructured":"Iwatsuki S, Shaw BW Jr, Starzl TE. Factors influencing survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 1993;218(1):52\u201362. https:\/\/doi.org\/10.1097\/00000658-199307000-00008.","journal-title":"Ann Surg"},{"issue":"5","key":"1403_CR12","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1245\/s10434-011-2102-8","volume":"19","author":"K Ito","year":"2012","unstructured":"Ito K, Ito H, Kemeny NE, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: Incidence, clinical features, and risk factors. Article. Ann Surg Oncol. 2012;19(5):1609\u201317. https:\/\/doi.org\/10.1245\/s10434-011-2102-8.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1403_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clcc.2011.03.029","volume":"11","author":"JS Bolton","year":"2012","unstructured":"Bolton JS, O\u2019Connell MJ, Mahoney MR, et al. Hepatic arterial infusion and systemic chemotherapy after multiple metastasectomy in patients with colorectal carcinoma metastatic to the liver: a North Central Cancer Treatment Group (NCCTG) phase II study, 92-46-52. Clin Colorectal Cancer. 2012;11(1):31\u20137. https:\/\/doi.org\/10.1016\/j.clcc.2011.03.029.","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"1403_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/sla.0b013e31822f4f88","volume":"254","author":"MG House","year":"2011","unstructured":"House MG, Kemeny NE, G\u00f6nen M, et al. Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg. 2011;254(6):851\u20136. https:\/\/doi.org\/10.1097\/sla.0b013e31822f4f88.","journal-title":"Ann Surg"},{"issue":"6","key":"1403_CR15","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/jco.2002.20.6.1499","volume":"20","author":"MM Kemeny","year":"2002","unstructured":"Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy\u2014an intergroup study. J Clin Oncol. 2002;20(6):1499\u2013505. https:\/\/doi.org\/10.1200\/jco.2002.20.6.1499.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1403_CR16","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/nejm199912303412702","volume":"341","author":"N Kemeny","year":"1999","unstructured":"Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039\u201348. https:\/\/doi.org\/10.1056\/nejm199912303412702.","journal-title":"N Engl J Med"},{"issue":"9","key":"1403_CR17","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/jco.2005.03.8166","volume":"24","author":"NE Kemeny","year":"2006","unstructured":"Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395\u2013403. https:\/\/doi.org\/10.1200\/jco.2005.03.8166.","journal-title":"J Clin Oncol"},{"issue":"35","key":"1403_CR18","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1200\/jco.2007.12.1764","volume":"25","author":"S Mocellin","year":"2007","unstructured":"Mocellin S, Pilati P, Lise M, Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol. 2007;25(35):5649\u201354. https:\/\/doi.org\/10.1200\/jco.2007.12.1764.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1403_CR19","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/1097-0142(19840315)53:6<1336::aid-cncr2820530620>3.0.co;2-o","volume":"53","author":"JE Niederhuber","year":"1984","unstructured":"Niederhuber JE, Ensminger W, Gyves J, Thrall J, Walker S, Cozzi E. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer. 1984;53(6):1336\u201343. https:\/\/doi.org\/10.1002\/1097-0142(19840315)53:6<1336::aid-cncr2820530620>3.0.co;2-o.","journal-title":"Cancer"},{"issue":"7","key":"1403_CR20","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/jco.1992.10.7.1112","volume":"10","author":"P Rougier","year":"1992","unstructured":"Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol. 1992;10(7):1112\u20138. https:\/\/doi.org\/10.1200\/jco.1992.10.7.1112.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1403_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1245\/s10434-016-5418-6","volume":"24","author":"M Dhir","year":"2017","unstructured":"Dhir M, Jones HL, Shuai Y, et al. Hepatic arterial infusion in combination with modern systemic chemotherapy is associated with improved survival compared with modern systemic chemotherapy alone in patients with isolated unresectable colorectal liver metastases: a case\u2013control study. Ann Surg Oncol. 2017;24(1):150\u20138. https:\/\/doi.org\/10.1245\/s10434-016-5418-6.","journal-title":"Ann Surg Oncol"},{"issue":"21","key":"1403_CR22","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/jco.2008.20.1301","volume":"27","author":"NE Kemeny","year":"2009","unstructured":"Kemeny NE, Melendez FDH, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465\u201371. https:\/\/doi.org\/10.1200\/jco.2008.20.1301.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1403_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/sla.0000000000000614","volume":"261","author":"MI D'Angelica","year":"2015","unstructured":"D\u2019Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer. Ann Surg. 2015;261(2):353\u201360. https:\/\/doi.org\/10.1097\/sla.0000000000000614.","journal-title":"Ann Surg"},{"issue":"13","key":"1403_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/s1470-2045(15)00122-9","volume":"16","author":"C Cremolini","year":"2015","unstructured":"Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306\u201315. https:\/\/doi.org\/10.1016\/s1470-2045(15)00122-9.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1403_CR25","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/s1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065\u201375. https:\/\/doi.org\/10.1016\/s1470-2045(14)70330-4.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1403_CR26","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1245\/s10434-021-11029-3","volume":"29","author":"FS Verheij","year":"2022","unstructured":"Verheij FS, Soares KC, Beets GL, et al. Timing of primary tumor resection in synchronous metastatic colon cancer patients undergoing hepatic arterial infusion pump placement. Ann Surg Oncol. 2022;29(3):2044\u201351. https:\/\/doi.org\/10.1245\/s10434-021-11029-3.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1403_CR27","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/j.clcc.2018.09.008","volume":"18","author":"O Abdel-Rahman","year":"2019","unstructured":"Abdel-Rahman O. Prognostic value of baseline ALBI score among patients with colorectal liver metastases: a pooled analysis of two randomized trials. Clin Colorectal Cancer. 2019;18(1):e61-8. https:\/\/doi.org\/10.1016\/j.clcc.2018.09.008.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"1403_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3109\/0284186x.2015.1101151","volume":"55","author":"G Maleux","year":"2016","unstructured":"Maleux G, Deroose C, Laenen A, et al. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: technical results, clinical outcome and factors potentially influencing survival. Acta Oncol. 2016;55(4):486\u201395. https:\/\/doi.org\/10.3109\/0284186x.2015.1101151.","journal-title":"Acta Oncol"},{"issue":"6 A","key":"1403_CR29","first-page":"707","volume":"20","author":"G Fiorentini","year":"2006","unstructured":"Fiorentini G, Cantore M, Rossi S, et al. Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. Vivo. 2006;20(6 A):707\u201310.","journal-title":"Vivo"},{"issue":"22","key":"1403_CR30","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1200\/JCO.2005.07.100","volume":"23","author":"N Kemeny","year":"2005","unstructured":"Kemeny N, Jarnagin W, Paty P, et al. Phase i trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888\u201396. https:\/\/doi.org\/10.1200\/JCO.2005.07.100.","journal-title":"J Clin Oncol"},{"key":"1403_CR31","unstructured":"Group E-ACR, Randomized Phase A. III Study of Systemic Therapy With or Without Hepatic Arterial Infusion for Unresectable Colorectal Liver Metastases: The PUMP Trial. Updated November 5, 2024. Accessed July 2, 2025. https:\/\/www.clinicaltrials.gov\/study\/NCT05863195"},{"issue":"3","key":"1403_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030667","volume":"10","author":"L L\u00e1szl\u00f3","year":"2021","unstructured":"L\u00e1szl\u00f3 L, Kurilla A, Tak\u00e1cs T, et al. Recent updates on the significance of KRAS mutations in colorectal cancer biology. Cells. 2021;10(3):667. https:\/\/doi.org\/10.3390\/cells10030667.","journal-title":"Cells"},{"issue":"5","key":"1403_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.21037\/cco.2019.08.16","volume":"8","author":"CW Steele","year":"2019","unstructured":"Steele CW, Whittle T, Smith JJ. Review: KRAS mutations are influential in driving hepatic metastases and predicting outcome in colorectal cancer. Chin Clin Oncol. 2019;8(5):53\u201353. https:\/\/doi.org\/10.21037\/cco.2019.08.16.","journal-title":"Chin Clin Oncol"},{"issue":"4","key":"1403_CR34","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1101\/gad.293449.116","volume":"31","author":"AT Boutin","year":"2017","unstructured":"Boutin AT, Liao W-T, Wang M, et al. Oncogenic\u2009<\u2009i\u2009>\u2009Kras\u2009drives invasion and maintains metastases in colorectal cancer. Genes Dev. 2017;31(4):370\u201382. https:\/\/doi.org\/10.1101\/gad.293449.116.","journal-title":"Genes Dev"},{"key":"1403_CR35","doi-asserted-by":"publisher","unstructured":"Golas MM, Gunawan B, Gutenberg A, et al. Cytogenetic signatures favoring metastatic organotropism in colorectal cancer. Nat Commun. 2025;16(1). https:\/\/doi.org\/10.1038\/s41467-025-58413-1.","DOI":"10.1038\/s41467-025-58413-1"},{"issue":"3","key":"1403_CR36","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1188\/18.CJON.340-346","volume":"22","author":"D Italiano","year":"2018","unstructured":"Italiano D. Hepatic arterial infusion pump: complications and nursing management regarding use in patients with colorectal cancer. Clin J Oncol Nurs. 2018;22(3):340\u20136. https:\/\/doi.org\/10.1188\/18.CJON.340-346.","journal-title":"Clin J Oncol Nurs"},{"issue":"4","key":"1403_CR37","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/jso.24898","volume":"117","author":"LM Pak","year":"2018","unstructured":"Pak LM, Kemeny NE, Capanu M, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. J Surg Oncol. 2018;117(4):634\u201343. https:\/\/doi.org\/10.1002\/jso.24898.","journal-title":"J Surg Oncol"},{"key":"1403_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5515-6","author":"FE Buisman","year":"2019","unstructured":"Buisman FE, Homs MYV, Gr\u00fcnhagen DJ, et al. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases \u2013 the multicenter randomized controlled PUMP trial. BMC Cancer. 2019. https:\/\/doi.org\/10.1186\/s12885-019-5515-6.","journal-title":"BMC Cancer"},{"key":"1403_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00353-4","author":"FA Zeineddine","year":"2023","unstructured":"Zeineddine FA, Zeineddine MA, Yousef A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023. https:\/\/doi.org\/10.1038\/s41698-023-00353-4.","journal-title":"NPJ Precis Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01403-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01403-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:56:30Z","timestamp":1768974990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01403-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01403-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7255848\/v1","asserted-by":"object"}]},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective chart review study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the University of Texas Southwestern Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The Institutional Review Board of the University of Texas Southwestern Medical Center granted a waiver of informed consent for this study due to its retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent To Participate"}},{"value":"The Institutional Review Board of the University of Texas Southwestern Medical Center granted a waiver for consent to publish.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent To Publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}